StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Reaktion

Methyl iodide → 3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-methoxyazetidine-1-carboxylic acid tert-butyl ester

HRID 1946130
Drucken

Reaktionsgleichung

Reaktionsgleichung von HRID 1946130
[C:1]([O:5][C:6]([N:8]1[CH2:11][C:10]([C:13]2[N:14]([CH3:39])[C:15]3[C:20]([N:21]=2)=[C:19]([N:22]2[CH2:27][CH2:26][O:25][CH2:24][CH2:23]2)[N:18]=[C:17]([N:28]2[C:32]4[CH:33]=[CH:34][CH:35]=[CH:36][C:31]=4[N:30]=[C:29]2[CH2:37][CH3:38])[N:16]=3)([OH:12])[CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[H-].[Na+].I[CH3:43]>C1COCC1>[CH2:37]([C:29]1[N:28]([C:17]2[N:16]=[C:15]3[C:20]([N:21]=[C:13]([C:10]4([O:12][CH3:43])[CH2:9][N:8]([C:6]([O:5][C:1]([CH3:4])([CH3:3])[CH3:2])=[O:7])[CH2:11]4)[N:14]3[CH3:39])=[C:19]([N:22]3[CH2:23][CH2:24][O:25][CH2:26][CH2:27]3)[N:18]=2)[C:32]2[CH:33]=[CH:34][CH:35]=[CH:36][C:31]=2[N:30]=1)[CH3:38]
KomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion

Komponenten

5

Edukt 3

HCID 6328Methyl iodide2×HCID 24758Sodium hydrideHCID 596058743-[2-(2-Ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester

Produkt 1

HCID 596061433-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-methoxyazetidine-1-carboxylic acid tert-butyl esterAusbeute 57,5 %

Reagenzien, Katalysatoren, Lösungsmittel

1
HCID 8028TetrahydrofuranLösungsmittel

Versuchsvorschrift

To a solution of 3-[2-(2-ethylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-3-hydroxyazetidine-1-carboxylic acid tert-butyl ester (208 mg, 0.39 mmol) in THF (3 mL) was added NaH (19 mg, 0.47 mmol, 60% dispersion in mineral oil) and the mixture allowed to stir for 5 min before the addition of iodomethane (29 μL, 66 mg, 0.47 mmol). The resulting mixture was allowed to stir for 3.5 h before further iodomethane (29 μL, 66 mg, 0.47 mmol) was added. The mixture was stirred for 16 h then concentrated in vacuo. The resulting residue was partitioned between EtOAc and H2O. The organic phase was dried (Na2SO4) and concentrated in vacuo. The resulting residue was purified by column chromatography (Si—PCC, EtOAc:cyclohexane, 40-80%) affording 714 as an oil (123 mg, 57%). LCMS (method I): RT 4.49 min, [M+H]+ 549.2. 1H NMR (CDCl3, 400 MHz): δ 7.99-7.90 (1 H, m), 7.74-7.64 (1 H, m), 7.25-7.16 (2 H, m), 4.60-4.40 (4 H, brd m), 4.18 (2 H, d, J=9.17 Hz), 3.82-3.81 (6 H, m), 3.71 (3 H, s), 3.29 (2 H, t, J=7.54 Hz), 3.07 (3 H, s), 1.42-1.33 (12 H, m).

Aufarbeitung

  1. additionwas added
  2. concentrationthen concentrated in vacuo
  3. customThe resulting residue was partitioned between EtOAc and H2O
  4. dry with materialThe organic phase was dried (Na2SO4)
  5. concentrationconcentrated in vacuo
  6. customThe resulting residue was purified by column chromatography (Si—PCC, EtOAc:cyclohexane, 40-80%)

Quellen und Nachweise

ORD-Eintrag
ord-4ff9e6f37cf34d55bb888f8a7eaa2776
Quelldatensatz
uspto-grants-2013_03
DOI
10.6084/m9.figshare.5104873.v1
Patentnummer
US08394796B2

Notizen zur Reaktion

Auf dieser SeiteKomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion